Advanced Search

 

Study ID Status Title Patient Level Data
SLGQ08/SLM8905 Completed An eight week randomized, double-blind, parallel group study to compare efficacy of salmeterol 50mcg BID, beclomethasone dipropionate 400mcg BID and salmeterol 50mcg plus beclomethasone dipropionate 400mcg BID in subjects with allergic asthma
SLGQ94 (521/180) Completed A multicenter, randomized, double-blind, parallel-group trial to evaluate the long-term efficacy and safety of inhaled salmeterol 50mg BID compared to short-acting b2-agonists as-needed in adult patients with asthma.
SLGQ98 Completed A 12 week randomized, double-blind, parallel group study evaluating effect of fluticasone propionate 500mcg BID, fluticasone propionate 200mcg plus salmeterol 50mcg BID or fluticasone propionate 200mcg BID for control of airway inflammation in subjects with asthma.
SLGS04 Completed A 12 week randomized, double-blind, parallel group study evaluating effect of salmeterol 50mcg BID or fluticasone propionate 100mcg BID for control of airway inflammation in subjects with asthma, when added to current inhaled corticosteroid therapy.
SLGS05 Completed Dose Response to Inhaled Salmeterol in Chronic Obstructive Pulmonary Disease
SLGS06 Completed A Single-Centre, Randomized, Placebo-Controlled, Double-Blind, Cross-Over Study to Compare the Efficacy and Safety of Salmeterol Xinafoate (100mg BID) with that of Placebo BID in Patients with Chronic Obstructive Pulmonary Disease
SLGT01 Completed A Multi-centre, 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study of 3 Twice-Daily Dosage Schedules of Inhaled GR33343G In Patients With Mild to Moderate Reversible Airways Obstruction
SLGT02 Completed Inhaled GR33343G In Reversible Airways Obstruction – Efficacy Over 3 Months and Safety Over 12 Months.
SLGT03 Completed A Double-Blind, Double-Dummy, Randomised, Multi-centre, Cross-over Study to Compare the Relative Efficacy of, and Tolerance to, 50mcg Inhaled GR33343G With Individually Dose-Titrated, Sustained-Release Theophylline (THEODUR®), Administered 12-Hourly, in Patients With Moderate Reversible Airways ...
SLGT04 Completed A Multi-centre, Randomised, Parallel-Group, Double-Blind Study Comparing Inhaled GR33343G 50mcg and 100mcg Twice Daily for 3 Months in Patients With Moderate to Severe Reversible Airways Obstruction
SLGT05 Completed Assessment of the Comparability of Metered-Dose Inhaler and Dry Powder Formulations of 50mcg GR33343G, Administered Twice Daily for 2 Weeks to Patients with Mild to Moderate Reversible Airways Obstruction.
SLGT06 Completed Inhaled GR33343G in Reversible Airways Obstruction – Efficacy and Safety Over Three Months: A Double-Blind, Parallel-Group Study Comparing Dry Powder Formulations of Inhaled GR33343G (50mcg) Administered Twice a Day and Inhaled Salbutamol (400mcg) Administered Four Times a Day
SLGT09 Completed A Study to Assess the Handling of a New Dry Powder Delivery System Containing GR33343G
SLGT11 Completed Determination of the Efficacy of GR33343G (50mcg Twice Daily) Administered From a Metered-Dose Inhaler in the Elderly.
SLGT12 Completed Determination of the Efficacy of GR33343G (50mcg Twice Daily) Administered From a Metered Dose Inhaler in the Elderly.
SLGT13 Completed A Double-blind, Three-Way Crossover Study Comparing GR33343G 25mcg BID, 50mcg BID, and Placebo in the Treatment of Childhood Asthma.
SLGT39 Completed A Multi-Centre, Randomised, Double-Blind, Parallel-Group Study to Compare the Efficacy and Tolerability of Salmeterol (50mg BID) Administered by Pressurised Inhaler Propelled by a Mixture of Propellants 11 and 12 or by an Alternative Propellant, GR106642X in Adult Patients with…
SLGT40 Completed A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Equivalence of Salmeterol 100mg Administered by Pressurised Inhaler Propelled by a Mixture of Propellants 11 and 12 or an Alternative Propellant, GR106642X in the Protection From…
SLGT41 Completed A Multi-Centre, Randomised, Double-Blind, Parallel Group Study to Compare the Efficacy and Tolerability of Salmeterol (50mg bd) Administered by Pressurised Inhaler Propelled by a Mixture of Propellants 11 and 12 or by an Alternative Propellant, GR106642X for a Period of …
SLGT42 Completed A Multi-National, Multi-Centre, Randomised, Double-Blind, Parallel Group Study to Compare the Efficacy and Tolerability of Salmeterol (50mg bd) Administered by Pressurised Inhaler Propelled by a Mixture of Propellants 11 and 12 or by an Alternative Propellant, GR106642X for…
SLGT43 Completed A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Equivalence of Salmeterol 50mg Administered by Pressurised Inhaler Propelled by a Mixture of Propellants 11 and 12 or an Alternative Propellant, GR106642X in the Protection From…
SLM8901 Completed A Single-Dose, Double-Blind, Placebo-Controlled Cross-over Study to Determine the Efficacy and Duration of Action of Inhaled Salmeterol Xinafoate 50mcg Against Methacholine-Induced Bronchoconstriction in Children with Reversible Airways Obstruction
SLMF4003 Completed Contribution of salmeterol in uncontrolled asthma in children
SLMF4010 Completed Multicentre, randomised, parallel group, placebo-controlled, double-blind, study, stratified on tobacco status at enrollment, evaluating during 6 months the efficacy of salmeterol powder for inhalation, 50 μg two times per day for the reduction of thoracic distension in subjects with chronic obstructive pulmonary disease (COPD)
SLMP03 Completed A single centre, randomised, double-blind, parallel group, placebo controlled study, to evaluate the effect of inhaled salmeterol xinafoate (50micrograms bd from a Diskhaler) on variations in bronchoconstriction induced by methacholine, in paediatric patients with mild to moderate asthma.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.